Kane Biotech Inc. Stock

Equities

KNE

CA4838092084

Biotechnology & Medical Research

Market Closed - Toronto S.E. 02:06:36 2024-05-28 pm EDT 5-day change 1st Jan Change
0.125 CAD 0.00% Intraday chart for Kane Biotech Inc. -16.67% +56.25%
Sales 2022 2.67M 1.95M Sales 2023 149K 109K Capitalization 10.55M 7.72M
Net income 2022 -3M -2.2M Net income 2023 -5M -3.66M EV / Sales 2022 6.37 x
Net Debt 2022 5.76M 4.22M Net Debt 2023 8.51M 6.23M EV / Sales 2023 128 x
P/E ratio 2022
-2.79 x
P/E ratio 2023
-2.02 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 65.07%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Kane Biotech Inc.

1 week-16.67%
Current month+4.17%
3 months+19.05%
6 months+66.67%
Current year+56.25%
More quotes
1 week
0.12
Extreme 0.12
0.15
1 month
0.12
Extreme 0.12
0.16
Current year
0.07
Extreme 0.07
0.17
1 year
0.05
Extreme 0.05
0.17
3 years
0.05
Extreme 0.05
0.20
5 years
0.00
Extreme 0
0.26
10 years
0.00
Extreme 0
0.58
More quotes
Managers TitleAgeSince
Chief Executive Officer - 16-06-01
Director of Finance/CFO - 17-09-04
Chief Tech/Sci/R&D Officer 73 22-04-04
Members of the board TitleAgeSince
Director/Board Member - 10-09-14
Chairman 59 Feb. 19
Director/Board Member - 20-05-19
More insiders
Date Price Change Volume
24-05-28 0.125 0.00% 8,000
24-05-27 0.125 -3.85% 126,000
24-05-24 0.13 -13.33% 294,000
24-05-23 0.15 +3.45% 3,013
24-05-22 0.145 -3.33% 374,056

Delayed Quote Toronto S.E., May 28, 2024 at 02:06 pm EDT

More quotes
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.
More about the company